{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:26:48Z","timestamp":1787909208906,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jneuroim.2015.03.022","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T22:52:59Z","timestamp":1428619979000},"page":"118-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Severe disease reactivation in four patients with relapsing\u2013remitting multiple sclerosis after fingolimod cessation"],"prefix":"10.1016","volume":"282","author":[{"given":"Benjamin","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Rauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Luetzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Farenkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Stich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.03.022_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/00207454.2011.622452","article-title":"Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab","volume":"122","author":"Baumgartner","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study","volume":"19","author":"Boriello","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0090","series-title":"26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 13\u201316 October 2010, Gothenburg, Sweden","article-title":"Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Abstract book","author":"De Vera","year":"2010"},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0020","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00415-012-6744-7","article-title":"Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients","volume":"260","author":"Ghezzi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0030","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1212\/WNL.0b013e3182735d24","article-title":"Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod","volume":"79","author":"Gross","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0035","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1177\/1352458512454773","article-title":"Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases","volume":"18","author":"Hakiki","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","article-title":"Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment","volume":"69","author":"Havla","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2010.06.005","article-title":"Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients","volume":"137","author":"Johnson","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00415-014-7558-6","article-title":"Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE","volume":"262","author":"Kaufman","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0060","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10072-014-1800-y","article-title":"Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia","volume":"35","author":"La Mantia","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0065","article-title":"Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning","author":"Martinelli","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11910-011-0216-9","article-title":"Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions","volume":"11","author":"Mehling","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0080","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00415-013-6933-z","article-title":"Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient","volume":"260","author":"Piscolla","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ene.12195","article-title":"Rebound of disease activity during pregnancy after withdrawal of fingolimod","volume":"20","author":"Sempere","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0095","series-title":"29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2\u20135 October 2013, Copenhagen, Denmark","first-page":"548","article-title":"Clinical and magnetic resonance imaging disease activity after fingolimod discontinuation. Abstract book","author":"Vollmer","year":"2013"},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1468-1331.2011.03574.x","article-title":"Natalizumab discontinuation: an increasingly tricky proposition","volume":"19","author":"West","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2015.03.022_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0033-1343794","article-title":"Fingolimod therapy for multiple sclerosis","volume":"33","author":"Willis","year":"2013","journal-title":"Semin. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:25:36Z","timestamp":1759047936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":21,"alternative-id":["S0165572815000892"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.03.022","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe disease reactivation in four patients with relapsing\u2013remitting multiple sclerosis after fingolimod cessation","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}